<DOC>
	<DOCNO>NCT00486278</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , Japan , North South America . The aim trial evaluate safety efficacy activate recombinant human factor VII analogue ( vatreptocog alfa ( activate ) ) haemophilia patient inhibitor .</brief_summary>
	<brief_title>Haemophilia Patients With Inhibitors Being Treated Acute Joint Bleeds</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>12 year age old ( least 18 year Croatia , France United Kingdom ( UK ) ) Clinical diagnosis congenital haemophilia A B current positive inhibitor titre know peak inhibitor 5 Bethesda unit ( BU ) ( present past ) human FVIII IX know antihuman FVIII IX anamnestic response Minimum 2 joint bleeds ( haemarthroses ankle , knee , elbow ) require haemostatic drug treatment within previous 6 month , least 4 joint bleeds ( hemarthroses ankle , knee , elbow ) require haemostatic drug treatment within previous 12 month trial entry Known allergy rFVIIa , and/or suspect allergy trial product Platelet count low 50,000 mm^3 base medical record trial entry ( visit 1 ) Any clinical sign history thromboembolic event Advanced atherosclerotic disease Severe liver disease base medical record within past 12 month trial entry ( Visit 1 ) , define alanine aminotransferase ( ALAT ) 3 time upper limit normal reference range Known active pseudo tumour ( document bleed require treatment within last 3 month Subject ( major ) surgical procedure 30 day prior screen trial . a. Catheter , port dental extraction count surgery exclude subject</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>